Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-05-11 15:59 |
Compugen to Participate at SITC’s Targets for Cancer Immunotherapy: A Deep Dive…
|
English | 106.7 KB | ||
| 2021-05-11 15:59 |
Compugen to Participate at SITC’s Targets for Cancer Immunotherapy: A Deep Dive…
|
English | 35.9 KB | ||
| 2021-05-10 15:59 |
Expansion of Research Collaboration with Johns Hopkins University for a Novel M…
|
English | 117.7 KB | ||
| 2021-05-10 15:59 |
Expansion of Research Collaboration with Johns Hopkins University for a Novel M…
|
English | 35.9 KB | ||
| 2021-05-03 15:59 |
Compugen to Release First Quarter 2021 Results on
Thursday, May 13, 2021
|
English | 80.6 KB | ||
| 2021-05-03 15:59 |
Compugen to Release First Quarter 2021 Results on
Thursday, May 13, 2021
|
English | 35.9 KB | ||
| 2021-04-29 15:59 |
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the America…
|
English | 87.1 KB | ||
| 2021-04-29 15:59 |
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the America…
|
English | 36.0 KB | ||
| 2021-04-27 15:59 |
Compugen Publishes Preclinical Data Demonstrating
Therapeutic Potential of COM…
|
English | 136.9 KB | ||
| 2021-04-27 15:59 |
Compugen Publishes Preclinical Data Demonstrating
Therapeutic Potential of COM…
|
English | 35.9 KB | ||
| 2021-03-09 14:59 |
Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis …
|
English | 133.8 KB | ||
| 2021-03-09 14:59 |
Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis …
|
English | 35.9 KB | ||
| 2021-03-08 14:59 |
to Present at the Oppenheimer 31st
Annual Healthcare Conference
|
English | 83.1 KB | ||
| 2021-03-08 14:59 |
to Present at the Oppenheimer 31st
Annual Healthcare Conference
|
English | 35.9 KB | ||
| 2021-02-26 01:36 |
Form 20-F for 2020
|
English | 2.3 MB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
